Aim 1	To use an MSC survival assay followed by vagus motoneuron outgrowth testing to identify an individual NF that promotes muscle stem cell survival and enhances vagus motoneuron regeneration.
Aim 2.	To construct a gene transfer vector encoding therapeutic NF, with resultant NF secretion from transduced primary MSCs in vitro.
Aim 3.	To determine post-RLN injury therapeutic outcomes in a time-dependent fashion after NF-secreting autologous MSCs are injected into acutely denervated laryngeal adductor muscles to promote reinnervation and localized neurotoxin is injected into the posterior cricoarytenoid muscle (PCA) to inhibit antagonistic reinnervation.